A Phase 1/2 interventional study of Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MCRC), sponsored by Bristol-Myers Squibb. Completed at 12 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-04.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 119th largest by enrollment of the 185 interventional ones that give a count, is one of 8 that started in 2008, is one of 20 in phase 1/2, and was the 58th registered.
6,545 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Verastem, Inc. · Sites in United States, Australia
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 131 · Phase 3 33 · Phase 4 4
First in 1999; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 60 across the 185 interventional studies. Of the 108 that completed or were terminated, 29 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 187 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
29 studies in Colorectal Neoplasms by Bristol-Myers Squibb: 4 open now, 9 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 24th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2008, is one of 10 in phase 1/2, and was the 4th registered.
Bristol-Myers Squibb’s Colorectal Neoplasms studies by the year they started, since 2002.
6 of the studies testing cetuximab in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06226857Phase 3City Clinical Oncology Hospital No 1Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer | 2026-12-31 |
| NCT06321081Beijing HospitalICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | 2026-12-30 |
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
| NCT06411600Vall d'Hebron Institute of OncologyCombination Therapy for BRAF-V600E Metastatic CRCm | 2027-05-01 |
| NCT07659795Verastem, Inc.A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 187 studies testing cetuximab in Colorectal Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 29 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC)
Part 2: To compare median duration of progression free survival (PFS)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cetuximab + Irinotecan + Brivanib OR Cetuximab + Irinotecan + Brivanib Placebo
Drug: Cetuximab · Drug: Irinotecan · Drug: Brivanib · Drug: Brivanib Placebo
Cetuximab + Irinotecan + Brivanib OR Cetuximab + Irinotecan + Brivanib Placebo
Drug: Cetuximab · Drug: Irinotecan · Drug: Brivanib · Drug: Brivanib Placebo
IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
Also known as: Erbitux, BMS-564717
IV solution, IV, Q3W, 350 mg/m2, until progression
Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
Oral, tablet, QD, until progression
Pharmacokinetics and markers of exploratory coagulation pathways will be conducted during this trial
Time frame: PK C1D1-C2-D3, biomarker throughout the study
Safety and tolerability of interventions will be collected
Time frame: throughout the study on Part II
Efficacy on tumor progression and progression free survival will be collected on all enrolled subjects
Time frame: throughout the study on Part II
The record gives a start of May 2008, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cetuximab · Irinotecan · Brivanib